Fenghuang Zhan
Professor
University of Arkansas for Medical Sciences
faculty
Internal Med, College of Medicine
Research Areas
Is this your profile? Verify and claim your profile
Biography and Research Information
OverviewAI-generated summary
Fenghuang Zhan's research focuses on the molecular mechanisms underlying the progression and development of multiple myeloma and other B cell malignancies. His work investigates how specific genes and cellular pathways contribute to tumor growth, chromosomal instability, and the formation of bone lesions associated with multiple myeloma. This includes studying the role of HNRNPA2B1 in promoting myeloma progression through AKT3 expression and the involvement of CHEK1 and circCHEK1_246aa in inducing chromosomal instability.
Further research by Zhan explores the evolutionary pathways leading to multiple myeloma and disparities in treatment access, such as the geographic and racial differences in access to CAR-T cell and bispecific antibody trials. He also investigates the modulation of protein deubiquitination by TRIP13 in the acceleration of B cell malignancies. His work has been supported by federal grants, including funding from the NIH/National Cancer Institute for research on novel NEK2 signaling pathways in myeloma progression.
Zhan is a highly cited researcher with an h-index of 66 and over 435 publications. He maintains active collaborations with several researchers at the University of Arkansas for Medical Sciences, including John D. Shaughnessy Jr., Guido Tricot, Sharmilan Thanendrarajan, and Maurizio Zangari, with whom he has co-authored numerous publications.
Metrics
- h-index: 66
- Publications: 435
- Citations: 18,873
Selected Publications
- Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025) DOI
- International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma (2025) DOI
- Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma (2024) DOI
- Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2024) DOI
- Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma (2024) DOI
- A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024) DOI
- Development and validation of an individualized and weighted Myeloma Prognostic Score System (<scp>MPSS</scp>) in patients with newly diagnosed multiple myeloma (2024) DOI
- The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting CST6 Against Multiple Myeloma and Suppresses Osteolytic Lesions (2023) DOI
- Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma (2023) DOI
- Type 2 Cystatins and Their Roles in the Regulation of Human Immune Response and Cancer Progression (2023) DOI
- Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines (2023) DOI
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma (2023) DOI
- Three years (yrs) maintenance with bortezomib, lenalidomide, and dexamethasone (RVD) in multiple myeloma (MM): Results of Total Therapy (TT) IIIB. (2023) DOI
- Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols. (2023) DOI
- Variability of definition of high‐risk multiple myeloma across phase III clinical trials (2023) DOI
Federal Grants 1 $330,316 total
Grants & Funding
- NEK2 Over-expression Causes Drug Resistance in Myeloma NIH Principal Investigator
- Biological Validation of Candidate Myeloma Driver Genes NIH/Nat. Cancer Institute - Pass Through: Medical College of Wisconsin Principal Investigator
- Novel NEK2 signaling pathways in myeloma progression NIH Principal Investigator
- Gene expression profiling vs MRD assessment in Myeloma NIH Co-Investigator
- U54 - Administrative Core NIH/Nat. Cancer Institute - Pass Through: Baylor College of Medicine Principal Investigator
- Center for Molecular Interactions in Cancer (CMIC) NIH Co-Investigator
- U54 - Bioinformatics Core NIH/Nat. Cancer Institute - Pass Through: Baylor College of Medicine Principal Investigator
- Targeting NEK2 Enables Immune Checkpoint Blockade in High-Risk/Relapsed Myeloma The Paula and Rodger Riney Foundation Principal Investigator
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics